Morgan Stanley analyst Sean Laaman upgrades ResMed (NYSE:RMD) from Equal-Weight to Overweight and announces $169price target.A great result - treated like ..Copyright © Benzinga. All rights reserved. Write to [email protected] with any questions about this content. Benzinga does not provide investment advice.
© 2023 Benzinga Newswires. Benzinga does not provide investment advice. All rights reserve
5% layoff. Margins will see better days
lets have some RMD..
First Quarter (23/24) Results, page-31
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$31.89 |
Change
0.160(0.50%) |
Mkt cap ! $20.24B | |||
| Open | High | Low | Value | Volume |
| $31.57 | $31.91 | $31.55 | $26.14M | 821.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 155 | $31.88 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $31.90 | 8959 | 1 |
View Market Depth
| Last trade - 16.10pm 13/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$31.88 |
Change
0.160 ( 0.25 %) |
||||
| Open | High | Low | Volume | ||
| $31.57 | $31.91 | $31.57 | 243046 | ||
| Last updated 15.59pm 13/06/2024 ? | |||||
| RMD (ASX) Chart |